ATOS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Atossa Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerATOS

Market Cap44.0M

Cash RunwayRunway 6-12 months

Next Catalyst2026-11

Public Research Snapshot

Atossa Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for ForeCYTE Breast Aspirator in Breast Neoplasms (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Evidence from Clinical Trials	advanced, ER-positive disease	n/a	Phase 1	Public pipeline row
Fulvestrant	Female Breast Carcinoma \| Female Ductal Carcinoma In Situ	n/a	Phase 2	Public pipeline row
Nipple aspirator	Breast Cancer \| Preneoplastic Conditions \| Ductal Carcinoma in Situ	n/a	n/a	Public pipeline row
ForeCYTE Breast Aspirator	Breast Neoplasms	n/a	Phase 3	Public pipeline row
Z-Endoxifen	Breast Density	n/a	Phase 2	Public pipeline row
(Z)-endoxifen	n/a	n/a	Phase 2	Public pipeline row
AT-301B	Healthy	n/a	Phase 1	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2026-11	(Z)-endoxifen	Low
Data Readout	Timing not specified	n/a	Low
Corporate Update	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT02121873	n/a	COMPLETED	6	2011-09
NCT02218385	n/a	COMPLETED	52	2014-08
NCT02539615	Phase 3	WITHDRAWN	n/a	2015-12
NCT02540330	Phase 2	TERMINATED	3	2020-08-13
NCT04519788	Phase 1	COMPLETED	32	2020-12-08
NCT05068388	Phase 2	ACTIVE_NOT_RECRUITING	240	2024-08-28
NCT05607004	Phase 2	RECRUITING	87	2026-11

Scientific Context

catalyst_type | Data Readout
catalyst_type | Corporate Update
catalyst_type | Data Readout
catalyst_type | Corporate Update
conditions | Female Breast Carcinoma | Female Ductal Carcinoma In Situ

Want the full ATOS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.